On the other hand

December 22, 2019 by Michael Kuttner
Read on for article

During the current session of the United Nations General Assembly, no fewer than EIGHTEEN resolutions against Israel will be debated and voted on.

Contrast this with ONE resolution each on Iran, Syria, North Korea, Myanmar, the USA (condemning them for the embargo on Cuba) and TWO resolutions on Crimea. That makes a grand total of SEVEN resolutions for the rest of the world!!

While this worthless organization has nothing better to do, Israel, despite all obstacles forges ahead with improving the lives of humanity.


 After its product was selected earlier this year as one of Time magazine’s 100 best inventions for 2019, Israeli startup Theranica, the developer of a medical device for the treatment of acute migraine, has been chosen by New York data company CB Insights as one of next year’s 36 startup “game-changers.”

The Netanya, Israel-based firm developed the Nerivio, a device worn on the upper arm that uses smartphone-controlled electronic pulses to wirelessly stimulate the body’s neural pathway at the onset of a migraine. The device is currently available by prescription in the US in some headache and migraine clinics, and will be available in Israel in April, the firm said last month.



 Israel’s National Infrastructure Committee on Monday green-lighted construction of a desalination plant in the Western Galilee — Israel’s sixth. The Western Galilee has suffered from years of low rainfall and has been unable to receive desalinated water from plants further south because of the difficulties and cost of building infrastructure to move the water over the Carmel Ridge.

To meet the challenges of reduced rainfall and multi-year droughts as the climate warms, Israel has built five desalination plants — in Ashkelon, Ashdod, Palmachim, Sorek and Hadera. These supply around 80 per cent of the country’s drinking water. Mekorot, the national water company, receives the water from the plants and channels it into the national water carrier.

A contract for the seventh plant, alongside the Sorek facility, is expected to be awarded soon.



Hadassah Medical Center in Jerusalem, a leader in the field of molecular diagnosis of tumours, has announced that its Molecular Pathology and Diagnostic Tumors department is now the first location in the Middle East and third outside of the United States to conduct a unique tumour diagnostic test within its own laboratories that help inform immunotherapy decisions.

The test, called FoundationOne-CDx (F1CDx), detects and identifies genetic changes in cancerous tumours such as substitutions, insertions, mutations, and alterations in 324 genes within a sample of the patient’s tissue. The test applies to all solid tumours including those of colorectal, breast, and ovarian cancers, as well as non-small-cell lung carcinoma and melanoma.

F1CDx is a leading FDA-approved molecular companion diagnostic test clinically and analytically validated in personalized medicine. Developed by US-based molecular insights company Foundation Medicine, a subsidiary of Swiss drugmaker Roche, the test collects a single tissue sample to analyze multiple gene alterations and helps match a patient’s genomic profile with targeted therapies to expand treatment options based on results. The procedure allows for more personalized therapy for the patient.

It’s now available in Israel for the first time. Foundation Medicine, which develops, manufactures and sells genomic profiling procedures based on next-generation technology, recently sent a team of representatives to Israel to help set up a laboratory system at Hadassah to ensure successful, accurate testing.



Although Samoa is far away from Israel this has not prevented a team of medical professionals flying to that South Pacific country in order to help combat the measles epidemic. Samoans have always shown a deep love for the Jewish State and therefore it is only natural that Israel extends a helping hand during a time of need.

Speak Your Mind

Comments received without a full name will not be considered
Email addresses are NEVER published! All comments are moderated. J-Wire will publish considered comments by people who provide a real name and email address. Comments that are abusive, rude, defamatory or which contain offensive language will not be published

Got something to say about this?

This site uses Akismet to reduce spam. Learn how your comment data is processed.